---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-415015"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2026-10-06T13:14:18+00:00"
generated_at: "2026-10-12T16:29:37.975755+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repligen closes BioLife Solutions buy for $11.25 cash plus 0.1442 RGEN shares per share

## Summary
- BioLife stockholders received $11.25 in cash plus 0.1442 shares of Repligen common stock per share, with cash in lieu of fractional shares.
- Mergers closed October 6, 2026 under the July 21, 2026 agreement; BioLife ceased to exist as a separate legal entity and became a Repligen subsidiary.
- BioLife Common Stock is being delisted from Nasdaq via Form 25, with a Form 15 planned to suspend reporting obligations under Sections 13 and 15(d).
- BioLife's CryoStor-led biopreservation media serves 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.
- Repligen says the deal adds a high-margin consumables franchise with recurring revenue and Asia Pacific reach; 2026 outlook impact to be detailed on the Q3 2026 earnings call.

## SEC filing metadata
- accession: 0001193125-26-415015
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2026-10-06T13:14:18+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/0001193125-26-415015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/d240327d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-415015
- JSON: https://secwatch.observer/filing/0001193125-26-415015.json
- Plain text: https://secwatch.observer/filing/0001193125-26-415015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.